Universal regulator adropin in patients with cardiorenal metabolic syndrome

Marta Kondratyuk; Natalia Pokrovska; Olena Radchenko; Anzhelika Filipyuk; Serhii Stadnik

Marta Kondratyuk Department of Internal Medicine No. 2, State Non-Profit Enterprise Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
Natalia Pokrovska Department of Internal Medicine No. 2, State Non-Profit Enterprise Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
Olena Radchenko Department of Internal Medicine No. 2, State Non-Profit Enterprise Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
Anzhelika Filipyuk Department of Internal Medicine No. 2, State Non-Profit Enterprise Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
Serhii Stadnik Department of Internal Medicine No. 2, State Non-Profit Enterprise Danylo Halytsky Lviv National Medical University, Lviv, Ukraine

Keywords: adropin, cardiorenal metabolic syndrome, stages, glomerular filtration rate, adropin correlations

Abstract

The level of an adropin is a cytokine regulator of energy balance and metabolism of lipids and carbohydrates in the patients with the cardiorenal metabolic syndrome (CRMs) progression has not been precisely established. The purpose of the study was to determine adropin levels in different stages of CRMs and its correlations with other parameters. 70 patients with arterial hypertension stage 2, grade 2 were examined under the control of the University bioethics commission in compliance with the Helsinki Declaration of Human Rights. They were divided into 5 groups (G0, 1, 2, 3a, 3) depending on the stage of CRMs and glomerular filtration rate. The serum adropin level was determined by enzyme-linked immunosorbent assay. A body mass index, triglyceride-glucose index, and de Ritis index were calculated too. The results were statistically processed. Worsening of blood pressure control was accompanied by an increase in blood adropin level. The level of adropin did not depend on the stage of CRMs signifacantly. Adropin levels correlated with clinical metabolic parameters of obesity, triglycerides, glucose, triglyceride-glucose index, de Ritis index, blood pressure levels, left atrial size and left ventricular wall thickness in different way during kidney function decreasing. Adropin’s correlations varied depending on the stage of CKMs, glomerular filtration rate, sex, age, and blood pressure control. The level of adropin did not depend on the stage of CRMs, but correlated differently with clinical and laboratory parameters.